Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Intraocular Pressure
Interventions: BOL-303259-X, Latanoprost; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Primary Open-angle Glaucoma, Cataract
Interventions: CyPass Micro-Stent implanted with CyPass 241-S applier, Cataract surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 20
States / cities: Phoenix, Arizona • Orange, California • Fort Collins, Colorado + 16 more

Conditions: Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
Interventions: Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution; Drug · Other
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Roswell, Georgia

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more

Conditions: Glaucoma
Interventions: Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Open Angle Glaucoma
Interventions: Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane; Drug
Lead sponsor: Center for Sight Las Vegas; Other
Eligibility: 40 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 13
States / cities: Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more

Conditions: Glaucoma, Open-Angle
Interventions: OMNI canaloplasty, Hydrus microstent; Device
Lead sponsor: Ridge Eye Care; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Marysville, California • Oroville, California • Paradise, California + 1 more

Conditions: Glaucoma, Primary Open Angle, Cataract
Interventions: Intracanalicular Dexamethasone, 0.4 mg insert; Drug
Lead sponsor: Wolstan and Goldberg Eye Associates; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Torrance, California

Conditions: Glaucoma, Open-Angle
Interventions: Travoprost Intraocular Implant, iStent infinite, Sham procedure; Drug · Device · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Pigmentary Glaucoma, Primary Open Angle Glaucoma, Cataract
Interventions: Trabeculectomy, Trabeculectomy and cataract surgery, Cataract surgery; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: OTX-TIC; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Petaluma, California • Torrance, California • Roswell, Georgia + 2 more

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Glaucoma, Glaucoma, Open-Angle
Interventions: Repetitive, Transorbital Alternating Current Stimulation (rtACS), Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Palo Alto, California • New York, New York • Philadelphia, Pennsylvania

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Pilocarpine, Ofloxacin, Prednisolone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension
Interventions: Selective Laser Trabeculoplasty; Device
Lead sponsor: Northeastern State University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Tahlequah, Oklahoma

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 9
States / cities: Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more

Conditions: Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions: anterior segment OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Nanodropper adaptor, control; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 22
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 19 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo); Drug · Other
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more

Conditions: Open-angle Glaucoma
Interventions: PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham; Drug
Lead sponsor: Perfuse Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Post Approval Study of the CyPass System

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Clinical Outcomes in Cataract Surgery With OMNI Canaloplasty vs Cataract Surgery With OMNI Canaloplasty and Hydrus Stent

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

Travoprost Intraocular Implant + iStent Infinite

Autoimmune Dysregulation in Pigmentary Glaucoma

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

Topical Insulin for Glaucoma (TING2)

Electrical Stimulation for the Treatment of Glaucoma

Pilocarpine After Combined Cataract/Trabectome Surgery

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Imaging Lens Deposits in Exfoliation Syndrome

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

A Study of PER-001 in Participants With Open-Angle Glaucoma